浙江钱江生物化学股份有限公司 2025 年 5 月 26 日 | | | | 2025年第二次临时股东大会会议须知 2 | | --- | | 2025年第二次临时股东大会会议议程 3 | | 2025年第二次临时股东大会会议议案 4 | | 议案一：审议《关于选举张广冬先生为第十届董事会独立董事的议案》……………4 | 1 浙江钱江生物化学股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会 的顺利进行，根据《公司章程》、公司《股东大会议事规则》等相关法律法规的要求， 特制定本年度股东大会会议须知。 Zhejiang Qianjiang Biochemical Co., Ltd 二零二五年第二次临时股东大会会议资料 一、董事会以维护股东的合法权益、确保大会正常秩序和议事效率为原则，认真 履行《公司章程》中规定的职责。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务请出席 大会的股东或股东代理人（以下统称"股东"）及相关人员准时到达会场签到确认参 会资格。股东参会登记当天没有通过电话、邮件或传真方式登记的，不在签到表上登 ...

证券代码：600796证券简称：钱江生化公告编号：2025-021 浙江钱江生物化学股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 26 日 10 点 00 分 召开地点：浙江省海宁市海洲街道钱江西路 178 号钱江大厦本公司会议室 股东大会召开日期：2025年5月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规定执行。 (七)涉及公开征集股东投票权 无 二、 会议审议事项 本次股东大会审议议案及投票股东类型 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本 ...

一、董事会会议召开情况 浙江钱江生物化学股份有限公司（以下简称"公司"）十届董事会 2025 年 第二次临时会议于 2025 年 5 月 6 日在公司会议室以现场和通讯相结合方式召开。 会议通知于 2025 年 4 月 27 日以书面及电子邮件方式发出。会议应到董事九名， 实到董事九名，董事钱宏声先生，独立董事裘益政先生、韦彦斐先生以通讯方式 表决。三名监事及高管人员列席了会议。会议由公司董事长孙玉超先生主持，本 次会议的召开符合《公司法》及《公司章程》的规定。 二、董事会会议审议情况 （一）审议通过了《关于提名公司第十届董事会独立董事候选人的议案》 本议案已经公司董事会提名委员会事前审议通过,并同意提交董事会审议。 表决结果：9 票同意，0 票反对，0 票弃权。 证券代码：600796 股票简称：钱江生化 编号：临 2025—020 浙江钱江生物化学股份有限公司 十届董事会 2025 年第二次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 报备文件 经独立董事候选人本人同意，公司董 ...

Financial Performance - The company reported a basic earnings per share of 0.0400 yuan for Q1 2025, representing a 33.33% increase compared to 0.0300 yuan in Q1 2024 [1] - The net profit for Q1 2025 was 0.31 billion yuan, a 6.9% increase from 0.29 billion yuan in Q1 2024 [1] - The total revenue for Q1 2025 was 3.78 billion yuan, showing a slight increase of 1.07% from 3.74 billion yuan in Q1 2024 [1] - The return on equity (ROE) for Q1 2025 was 0.93%, up from 0.91% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 11,698.65 million shares, accounting for 37.8% of the circulating shares, with an increase of 484.66 million shares compared to the previous period [1] - The largest shareholder, Haining Asset Management Company, holds 10,037.88 million shares, representing 32.43% of the total share capital, with no change [2] - New entrants among the top shareholders include Zhong Ge and Chen Hui, while notable exits include Zhang Huwen and Goldman Sachs [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

证券代码：600796 证券简称：钱江生化 公告编号：临 2025-019 浙江钱江生物化学股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 05 月 13 日 （星期二） 09:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 05 月 06 日 （星期二） 至 05 月 12 日 （星 期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 qjbioch@600796.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 浙江钱江生物化学股份有限公司（以下简称"公司"）已于 2025 年 4 月 19 日和 4 月 29 日分别发布公司 2024 年年度报告和 2025 年第 一季度报告，为便于广大投资者更 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 377,833,176.21, representing a 1.03% increase compared to CNY 373,985,726.46 in the same period last year[3] - Net profit attributable to shareholders was CNY 30,504,599.36, up 6.00% from CNY 28,777,812.43 year-on-year[3] - Basic and diluted earnings per share increased by 33.33%, both reaching CNY 0.04 per share[3] - The net profit for the first quarter of 2025 is CNY 24,235,411.57, an increase from CNY 20,691,710.04 in the same period of 2024, representing a growth of approximately 12%[17] - The total operating profit for the first quarter of 2025 is CNY 36,357,964.46, compared to CNY 28,421,173.25 in the first quarter of 2024, indicating a year-over-year increase of about 28%[17] Cash Flow - The net cash flow from operating activities improved by 32.16%, reaching CNY -64,988,506.34, compared to CNY -95,803,216.03 in the previous year[3] - The cash flow from operating activities for Q1 2025 is negative at CNY -64,988,506.34, an improvement from CNY -95,803,216.03 in Q1 2024[18] - The cash flow from investing activities shows a net outflow of CNY -106,255,013.03 in Q1 2025, compared to CNY -234,566,513.83 in Q1 2024, indicating a reduction in cash outflow by approximately 55%[19] - The cash flow from financing activities for Q1 2025 is positive at CNY 55,776,387.11, a significant turnaround from CNY -37,210,052.19 in Q1 2024[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,546,781,905.35, a slight decrease of 0.05% from CNY 7,550,919,451.11 at the end of the previous year[4] - Total liabilities decreased to CNY 3,965,302,556.61 as of March 31, 2025, compared to CNY 3,994,133,169.37 as of December 31, 2024, a reduction of approximately 0.73%[13] - Current assets totaled CNY 2,325,366,825.40 as of March 31, 2025, down from CNY 2,385,880,831.04 as of December 31, 2024, indicating a decrease of about 2.54%[12] - Cash and cash equivalents were CNY 820,899,581.33 as of March 31, 2025, down from CNY 948,498,660.85 as of December 31, 2024, reflecting a decline of approximately 13.5%[11] - The company reported a decrease in accounts receivable to CNY 1,015,814,544.06 as of March 31, 2025, compared to CNY 924,038,687.08 as of December 31, 2024, an increase of about 9.9%[11] Shareholder Equity - Shareholder equity attributable to shareholders was CNY 3,307,139,432.97, reflecting a 0.95% increase from CNY 3,276,177,178.18 at the end of the previous year[4] - The company’s total equity increased to CNY 3,581,479,348.74 as of March 31, 2025, from CNY 3,556,786,281.74 as of December 31, 2024, representing a growth of approximately 0.69%[13] Cost Management - The company has strengthened cost control measures, leading to reduced cash outflows for procurement and other expenses[6] - Total operating costs decreased to CNY 353,481,929.54 in Q1 2025 from CNY 357,218,304.26 in Q1 2024, reflecting a reduction of about 1.03%[16] - Research and development expenses increased to CNY 7,244,113.84 in Q1 2025, up from CNY 5,008,497.68 in Q1 2024, indicating a growth of approximately 44.5%[16] Shareholder Information - The top shareholder, Haining Water Investment Group Co., Ltd., holds 44.98% of the shares, totaling 389,756,986 shares[8] Non-Recurring Items - Non-recurring gains and losses totaled CNY 2,193,380.33, with significant contributions from asset disposal and government subsidies[6] Future Outlook - The company plans to continue focusing on improving cash flow management and reducing operational costs in the upcoming quarters[20]

证券代码：600796 股票简称：钱江生化 编号：临 2025—018 浙江钱江生物化学股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: ●被担保人名称： 浙江海云环保有限公司（以下简称"海云环保"），为公司的全资子公司 ●本次担保金额及已实际为其提供的担保余额 本次为海云环保提供的担保金额为 5,000 万元，已实际为其提供的担保余额 14,550 万元（包含本次担保） ●本次担保是否有反担保：否 ●对外担保逾期的累计数量：0 元 注册资本： 110,000 万元 浙江钱江生物化学股份有限公司（以下简称"公司"）分别于 2024 年 4 月 17 日和 2024 年 5 月 10 日，召开的十届七次董事会和 2023 年年度股东大会，审 议通过了《关于 2024 年度公司及子公司提供担保额度预计的议案》，同意 2024 年度公司及子公司预计提供担保的总额度不超过人民币 185,980 万元（包括新增 担保及已提供尚在担保期限内的存量担保金额），其中对海云环保新 ...

浙江钱江生物化学股份有限公司（以下简称"公司"）董事会今日收到公司 独立董事裘益政先生提交的书面辞职报告。裘益政先生因个人原因申请辞去公司 第十届董事会独立董事及所有董事会专门委员会职务，辞职后将不再担任公司任 何职务。截至本公告披露日，裘益政先生未持有公司股份。 裘益政先生辞职后将导致公司独立董事人数占公司董事会成员的比例低于 三分之一，根据《中华人民共和国公司法》《上市公司独立董事管理办法》及《公 司章程》等有关规定，在公司股东大会选举产生新任独立董事前，裘益政先生仍 将继续履行公司独立董事、董事会专门委员会的相关职责。 裘益政先生在担任公司独立董事期间恪尽职守、勤勉尽责，充分发挥自身专 业优势，在促进公司规范运作、健康发展等方面发挥了积极作用，公司及公司董 事会对裘益政先生任职期间为公司做出的贡献表示衷心感谢！ 浙江钱江生物化学股份有限公司 关于独立董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特此公告。 浙江钱江生物化学股份有限公司董事会 2025 年 4 月 25 日 证券代码：600796 ...

浙江钱江生物化学股份有限公司 Zhejiang Qianjiang Biochemical Co., Ltd 二零二四年年度股东大会会议资料 2025 年 5 月 9 日 | | | | 一、2024年年度股东大会会议须知 2 | | | | | | --- | --- | --- | --- | --- | | 二、2024年年度股东大会会议议程 3 | | | | | | 三、2024年年度股东大会会议议案 4 | | | | | | 议案一:审议《公司2024年度董事会工作报告》 4 | | | | | | 议案二：审议《公司2024年度监事会工作报告》 12 | | | | | | 议案三:审议《公司2024年度财务决算报告》 15 | | | | | | 议案四:审议《公司2024年度利润分配方案》 19 | | | | | | 议案五:审议《公司2024年年度报告及其摘要》 20 | | | | | | 议案六:审议《关于 2024年度董事薪酬的议案》 21 | | | | | | 议案七:审议 《关于 2024年度监事薪酬的议案》 22 | | | | | | 议案八:审议《关于变更会计师事务所 ...

Financial Overview - The total operating revenue for Qianjiang Biochemical in 2024 was 1.768 billion, a year-on-year decrease of 13.08% [2] - The net profit attributable to shareholders was 160 million, down 24.06% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 133 million, a decline of 35.18% year-on-year [2] - In Q4, the total operating revenue was 468 million, a decrease of 33.75% year-on-year [2] - The net profit attributable to shareholders in Q4 was 31.14 million, down 56.18% year-on-year [2] - The net profit after deducting non-recurring gains and losses in Q4 was 7.27 million, a significant drop of 90.5% year-on-year [2] Key Financial Indicators - Accounts receivable accounted for 577.51% of the net profit attributable to shareholders, indicating a high risk of collection [4] - Interest-bearing liabilities increased by 29.43% year-on-year to 2.627 billion [4] - The interest-bearing asset-liability ratio reached 31.11%, raising concerns about the company's debt repayment capacity [4] Cash Flow Situation - The company's cash and cash equivalents amounted to 948 million, an increase of 8.24% year-on-year [5] - The ratio of cash and cash equivalents to current liabilities was only 96.4%, indicating cash flow pressure [5] Main Business Analysis - The wastewater treatment and recycling business generated 499 million in revenue, accounting for 28.20% of total revenue with a gross margin of 44.66% [6] - The engineering installation and material sales business had revenue of 402 million, representing 22.76% of total revenue with a gross margin of 16.64% [6] - The bio-pesticide business generated 256 million in revenue, accounting for 14.50% of total revenue with a gross margin of 18.27% [6] - The steam and waste incineration businesses reported losses of 36.28 million and 12.47 million, respectively [6] Development Review and Outlook - In 2024, the company made progress in the ecological environment, bio-pesticides, and water operations sectors, but overall performance was poor [7] - The company plans to continue project construction, enhance technological innovation, and optimize industrial layout [7] - Industry competition, project investment risks, and safety and environmental risks remain areas of concern [7] Summary - Qianjiang Biochemical's financial performance in 2024 was weak, particularly in net profit and net profit after deducting non-recurring gains and losses [8] - The company needs to closely monitor accounts receivable collection and debt risks to ensure sustainable development in the future [8]